TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16959618
Drug: Ipratropium 20
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 20 microg four times daily from a metered dose inhaler
Study: 15221622
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of CR L-dopa and entacapone
Study: 15221622
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of entacapone (30 and 90 minutes) with CR L-dopa
Study: 11299402
Drug: Lateral sphincterotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral sphincterotomy under local anesthesia (topical anesthetic cream xylocaine 2% and local anesthesia)
Study: 8433253
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration with tetracycline root conditioning (100 mg/ml)
Study: 30558607
Drug: Per oral
Normalized name: Amino Acids/Copper Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per oral (p.o.) antibiotic monotherapy
Study: 30558607
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) antibiotic therapy followed by p.o. antibiotics
Study: 26809111
Drug: DEB-TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEB-TACE plus sorafenib 400 mg twice daily
Study: 22848896
Drug: Inward-inclined platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inward-inclined platform implants
Study: 22848896
Drug: Traditional external-hexagon
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional external-hexagon implants
Study: 22848896
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (external-hexagon implants)
Study: 22848896
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group (inward-inclined platform implants)
Study: 17287681
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) technology
Study: 11173127
Drug: Future improvements
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Future improvements in therapy
Study: 9760352
Drug: Protein-carbohydrate supplement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-carbohydrate supplement
Study: 7862879
Drug: Caffeine (178
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (178 mg)
Study: 26481174
Drug: NAVIGATE (comprehensive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAVIGATE (comprehensive, multidisciplinary, team-based treatment)
Study: 24168107
Drug: High mushroom
Approvals — FDA: no, EMA: no, PMDA: no
Description: High mushroom diet (treatment B)
Study: 24168107
Drug: No mushrooms
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mushrooms diet (treatment A)
Study: 22794203
Drug: 1-visit endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-visit endodontic treatment
Study: 22794203
Drug: 2-visit endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-visit endodontic treatment with calcium hydroxide medication
Study: 16051509
Drug: Modified Brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Brief Pain Inventory short form (BPI-sf) used daily in patients with osteoarthritis
Study: 11305520
Drug: Torsemide 20
Normalized name: torsemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide 20 mg/day
Study: 10577572
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg/day
Study: 9561978
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy including radiotherapy (16 patients) and sequential and intraventricular chemotherapy (methotrexate in 32 patients; cytarabine in 16; thiotepa in 6). Concurrent systemic chemotherapy was given to 12 patients.
Study: 18584198
Drug: Synacthen (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synacthen (0.25 mg, TX)
Study: 10735892
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m(2), gemcitabine 1,000 mg/m(2), and vinorelbine 25 mg/m(2) on days 1 and 8 every 3 weeks (PGV)
Study: 10735892
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m(2) on day 1 and gemcitabine 1,000 mg/m(2) on days 1, 8, and 15 every 4 weeks (PG)
Study: 10735892
Drug: Cisplatin 120
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 120 mg/m(2) on days 1 and 29 and vinorelbine 30 mg/m(2)/wk (PV)
Study: 1389513
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tamoxifen per day for 2 years
Study: 1389513
Drug: no drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: no drug treatment
Study: 2932205
Drug: Ketanserin (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (serotonin antagonist) for 3 days
Study: 2932205
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (no medication for 3 days)
Study: 2932205
Drug: Ergonovine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergonovine administered in incremental doses (0.0125 mg to 0.4 mg)
Study: 18320439
Drug: GnRH-a (triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-a (triptorelin 0.1 mg on the day of ovum pickup, on the day of embryo transfer, and three days thereafter)
Study: 24044802
Drug: Partial breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial breast irradiation (PBI) using interstitial multi-catheter high-dose-rate brachytherapy (4 Gy, twice a day for 4 days, until 32 Gy)
Study: 24044802
Drug: Partial breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial breast irradiation (PBI) using interstitial multi-catheter high-dose-rate brachytherapy
Study: 22053942
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum 900-1,500 mg/d
Study: 22053942
Drug: Sertraline 50-100
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-100 mg/d
Study: 15376564
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy plus octreotide 50 microg/h bolus and continuous infusion for 5 days (n=36)
Study: 15376564
Drug: Octreotide 50
Normalized name: octreotide 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 50 microg/h bolus and continuous infusion for 5 days (n=13)
Study: 15376564
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy only (banding and/or sclerotherapy) (n=43)
Study: 11783824
Drug: Multimodal biopsychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal biopsychosocial treatments including cognitive-behavioral and/or behavioral components
Study: 9338537
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terfenadine (120 mg) and ranitidine (300 mg)
Study: 9338537
Drug: Terfenadine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine alone (120 mg)
Study: 9338537
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terfenadine and ranitidine
Study: 3108622
Drug: Continuous nasoenteric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nasoenteric formula infusion
Study: 3108622
Drug: Intermittent nasoenteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nasoenteric formula infusion
Study: 30843450
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg/day
Study: 26324315
Drug: Bedoradrine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedoradrine (1200 μg)
Study: 23993034
Drug: Capacitive coupling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive coupling (CC) electrical stimulation
Study: 15381507
Drug: Multifactorial falls
Normalized name: Halls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial falls prevention programme including 3 months gait and balance training, medication review, podiatry and optometry
Study: 12934982
Drug: Citalopram (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (mean dose of 57.9 mg/day)
Study: 2371424
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled therapy (salbutamol and beclomethasone dipropionate)
Study: 2371424
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inhaled steroids and beta agonist
Study: 24460668
Drug: CLP 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLP 7.5 g/day
Study: 24460668
Drug: CLP 15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLP 15.0 g/day
Study: 24460668
Drug: CLP 25.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLP 25.0 g/day
Study: 24460668
Drug: CLP 15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLP 15.0 g/day under fasting conditions
Study: 19932775
Drug: Combination lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination lipid therapy
Study: 19932775
Drug: LDL cholesterol-lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL cholesterol-lowering and HDL cholesterol-increasing therapies
Study: 17241666
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.4 mg/ml) eyedrops, 1 drop 4 times a day for 3 weeks
Study: 17241666
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.4 mg/ml) eyedrops
Study: 15717519
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES solution, 5-6 ml/kg
Study: 15717519
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES solution, 5-6 ml/kg and 1.5% reamberin solution, 5 ml/kg
Study: 9817522
Drug: Ceftriaxone 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 4 g i.v. once daily
Study: 29672731
Drug: Adjunct AF
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct AF surgery (ablation)
Study: 18676384
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine (15 mg)
Study: 18676384
Drug: 0.75% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% levobupivacaine (15 mg)
Study: 30089160
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for 3 months
Study: 14518700
Drug: Indinavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir 800/100 mg with food
Study: 14518700
Drug: Indinavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir 800/100 mg on an empty stomach
Study: 10740135
Drug: Lamifiban bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamifiban bolus and infusion
Study: 1558466
Drug: Half-dose maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose maintenance of imipramine for 12 months
Study: 1558466
Drug: Acute-phase treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute-phase treatment with imipramine
Study: 28399909
Drug: Safety plan
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Safety plan on paper (Treatment as Usual, control)
Study: 26263592
Drug: Enhanced oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced oral health promotion program with toothpaste containing 1,450 ppm F‐ and 1.5% arginine
Study: 26263592
Drug: Enhanced oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced oral health promotion program with toothpaste containing 1,450 ppm F‐ and 1.5% arginine in cooperative schools
Study: 23857539
Drug: 10‐mg dinoprostone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg dinoprostone vaginal insert
Study: 16046015
Drug: Amiodarone 450
Normalized name: amiodarone 450 mg/250 mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 450 mg IV bolus
Study: 16046015
Drug: Digoxin 0.6
Normalized name: medigoxin 0.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.6 mg IV bolus
Study: 12819556
Drug: Estrogen-Only Replacement
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-Only Replacement Therapy (ERT)
Study: 10494188
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with hematopoietic blood stem cell support
Study: 8889439
Drug: Local, intra-arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local, intra-arterial infusion of insulin (0.3 mU dL-1 forearm volume min-1 for 180 min)
Study: 8889439
Drug: Local, intra-arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local, intra-arterial infusion of insulin
Study: 8889439
Drug: Combined infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined infusion of insulin and glucose (5%, 0.2 mL dL-1 min-1)
Study: 1894759
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (120 mg, single dose)
Study: 1894759
Drug: Isosorbide-5-mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (20 mg, twice daily)
Study: 23895557
Drug: Low-dose ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose ethanol (target BrAC = 40 mg%)
Study: 23895557
Drug: High-dose ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose ethanol (target BrAC = 100 mg%)
Study: 15182402
Drug: Strong capsules
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong capsules with red pepper
Study: 9306481
Drug: DTaP/PRP‐T combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP/PRP‐T combined vaccine
Study: 8457525
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g 13C‐labelled erythritol
Study: 8457525
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g 13C‐labelled glucose
Study: 8457525
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g 13C‐labelled lactitol
Study: 25742062
Drug: Systematic medication
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic medication review by a clinical pharmacist and clinical pharmacologist
Study: 25742062
Drug: Usual medication
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medication routine (control)
Study: 25742062
Drug: Systematic medication
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic medication review
Study: 23165582
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose adjustment of oral anticoagulants
Study: 23165582
Drug: Patients achieving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients achieving oral anticoagulation stability (n = 23)
Study: 20679166
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (IN‐MMAD) 0.2 mg/kg (max 10 mg)
Study: 20679166
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam (RD) 0.3 to 0.5 mg/kg (max 20 mg)
Study: 12427785
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299v (Proviva) administered orally for at least one week preoperatively and postoperatively
Study: 30664882
Drug: Intravenous scorpion
Normalized name: Antivenin, scorpion
DrugBank: Scorpion (centruroides) immune Fab2 antivenin (equine) (DB13905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous scorpion antivenom
Study: 30664882
Drug: Intramuscular scorpion
Normalized name: Antivenin, scorpion
DrugBank: Scorpion (centruroides) immune Fab2 antivenin (equine) (DB13905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular scorpion antivenom
Study: 23203544
Drug: Micro-pump (MP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-pump (MP) administration of epirubicin for 48 hours
Study: 23203544
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip (ID) administration of epirubicin for 1 hour
Study: 31736025
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 20 ml 0.25 % bupivacaine (10 ml for each level) preoperatively
Study: 27100333
Drug: Caffeine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (dose = 160 mg) administered in various conditions (coffee vs energy drink, different rates of consumption, and temperature)
Study: 27100333
Drug: Caffeine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (dose = 160 mg) administered in coffee
Study: 27100333
Drug: Caffeine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (dose = 160 mg) administered in energy drink
Study: 3044181
Drug: Piritramide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritramide (15 mg)
Study: 26820419
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (off MPH)
Study: 20833444
Drug: Etanercept (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (intermittent therapy)
Study: 18500561
Drug: Optimized tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized tablet (M-7) containing chitosan and hydroxypropyl methylcellulose phthalate
Study: 18500561
Drug: Marketed tablet
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed tablet
Study: 29442440
Drug: Behavioral Treatment
Normalized name: AspyreRx Digital Behavioral Therapeutic Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Treatment (BT)
Study: 15705006
Drug: Behavioral Treatment
Normalized name: AspyreRx Digital Behavioral Therapeutic Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Treatment (BT) (post hoc analysis)
Study: 15705006
Drug: Behavioral Treatment
Normalized name: AspyreRx Digital Behavioral Therapeutic Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Treatment (BT) (week 14)
Study: 12852711
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g PLT 3514 emulsion (0.75 g GLA + 0.5 g EPA)
Study: 12852711
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g PLT 3514 emulsion (1.13 g GLA + 0.75 g EPA)
Study: 10494189
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line treatment for Hodgkin's disease
Study: 8975400
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg orally three times a day for seven days
Study: 6140261
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg and 2 mg)
Study: 6140261
Drug: Clorazepate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate (7.5 mg and 15 mg)
Study: 26372680
Drug: Acute exacerbations,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute exacerbations, allergen-induced airway obstruction, and corticosteroid treatment
Study: 26372680
Drug: Allergen inhalation
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen inhalation effects on blood and sputum YKL-40 levels
Study: 18058479
Drug: Amlodipine maleate
Normalized name: Amlodipine Maleate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine maleate 10 mg
Study: 18058479
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 10 mg (Norvasc)
Study: 16118338
Drug: 17beta-estradiol (E2)
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol (E2) supplementation (2 mg/d for 8 days)
Study: 2680790
Drug: 3-drug therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-drug therapy (Adriablastine, Cisplatin, Cyclophosphamide)
Study: 2680790
Drug: Two-drug chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug chemotherapy without Cisplatin
Study: 9118661
Drug: Cisapride (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (60 mg initially followed by two doses of 30 mg at 8-hr intervals)
Study: 2949285
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 g administered once
Study: 2949285
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g administered once
Study: 26349552
Drug: Vancomycin plus
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin plus flucloxacillin (combination group)
Study: 26349552
Drug: Vancomycin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (standard therapy group)
Study: 26349552
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (vancomycin)
Study: 22441222
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (sham treatment with disconnected HVES equipment)
Study: 18420939
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg prednisolone daily in addition to disease-modifying anti-rheumatic drugs